Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...

Anthelminthic Agents

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...

Skin Cancer

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...

Drugs for Treatment of Ulcerative Colitis in IBD

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

[Translated article] Cross-Cultural Validation of the RosaQoL Scale in Spanish Language.

Actas dermo-sifiliograficas·2024

Same author

Cross-Cultural Validation of the RosaQoL Scale in Spanish Language.

Actas dermo-sifiliograficas·2024

Same author

Abdominal Pseudohernia Due to Herpes Zoster.

Actas dermo-sifiliograficas·2020

Same author

Recent Onset of Multiple Asymptomatic Brownish Papules.

Actas dermo-sifiliograficas·2019

Same author

Absolute Versus Relative Psoriasis Area and Severity Index in Clinical Practice.

Actas dermo-sifiliograficas·2019

Same author

Ziprasidone-induced sub acute cutaneous lupus erythematosus.

Lupus·2016

Search research articles

Related Experiment Video

Updated: Jun 16, 2026

Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians

Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians

Published on: March 14, 2014

[Bullous scabies responding to ivermectin therapy].

L Galvany Rossell¹, M Salleras Redonnet, P Umbert Millet

¹Servicio de Dermatología, Hospital Universitario Sagrat Cor, Barcelona, España. loidagalvany@gmail.com

Actas Dermo-Sifiliograficas

|January 30, 2010

Summary

This summary is machine-generated.

Bullous scabies, a rare blistering disease mimicking bullous pemphigoid, typically affects the elderly. This case highlights successful treatment with oral ivermectin, offering a new therapeutic option.

Related Experiment Videos

Last Updated: Jun 16, 2026

Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians

Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians

Published on: March 14, 2014

Area of Science:

Dermatology
Immunology

Background:

Bullous scabies is a rare blistering skin condition.
It often presents in elderly individuals and shares clinical, histological, and immunological similarities with bullous pemphigoid.

Observation:

A case of bullous scabies in a 72-year-old male patient is presented.
The patient exhibited clinical features indistinguishable from bullous pemphigoid.

Findings:

Literature review identified 24 previously reported cases of bullous scabies.
The presented patient's lesions demonstrated a positive response to oral ivermectin treatment.

Implications:

Oral ivermectin may be an effective treatment for bullous scabies.
Further research is warranted to understand the pathogenesis and optimal management of this rare condition.